Bio Path Holdings

Bio Path Holdings P/FCF

Delisted·Sep 10, 2026

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Bio Path Holdings (BPTH) as of Oct 20, 2026 is -0.05. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -0.05 — a change of 9.08% (lower).

P/FCF

-0.05

YoY

9.08%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Bio Path Holdings is 2024 -0.05 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Bio Path Holdings was 2023 -0.05 . It decreases by 9.08% lower compared to the previous year.

The Bio Path Holdings P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2017
-0.06 USD
Jan 1, 2018
-0.09 USD
Jan 1, 2019
-0.06 USD
Jan 1, 2020
-0.05 USD
Jan 1, 2021
-0.05 USD
Jan 1, 2022
-0.04 USD
Jan 1, 2023
-0.05 USD
Jan 1, 2024
-0.05 USD
The Bio Path Holdings P/FCF history
YEARP/FCFYoY
-0.05+9.08%
-0.05+31.11%
-0.04-33.97%
-0.05+10.44%
-0.05-23.56%
-0.06-27.16%
-0.09+38.33%
-0.06-0.11%
-0.06-37.05%
-0.10-26.23%
-0.14—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Path Holdings Stock analysis

What does Bio Path Holdings do? Bio-Path Holdings, Inc. develops therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) using its DNAbilize technology platform. The company's drug delivery system, DNAbilize, utilizes P-ethoxy, a DNA backbone modification that protects antisense drugs from enzymatic destruction in the body. This platform enables systemic distribution of antisense drug substances to target over-expressed proteins in blood diseases and solid organs. Bio-Path has three antisense drug candidates in development targeting over five different cancer disease indications. The company's primary revenue stream comes from the development and commercialization of its antisense drug candidates. These therapies are designed to treat specific blood cancers and solid organ diseases where proteins are over-expressed. Bio-Path's technology allows for targeted protein inhibition without systemic toxicity, making it suitable for treating multiple cancer indications. The company focuses on developing therapies for AML and CML, which are serious blood disorders requiring specialized treatment approaches. Bio-Path Holdings, Inc. is a biotechnology company headquartered in Bellaire, Texas, with 10 full-time employees. It utilizes its DNAbilize platform to create antisense drug candidates that target over-expressed proteins in various diseases. The company's technology enables systemic delivery of antisense therapies across the body, allowing for reduction or elimination of disease-causing proteins. This approach is intended to provide targeted treatment for multiple cancer indications including AML and CML. Bio Path Holdings is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Path Holdings stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Bio Path Holdings is -0.05 in 2024.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Bio Path Holdings changed from -0.05 to -0.05, representing a 9.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Bio Path Holdings since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Bio Path Holdings with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bio Path Holdings

All Key Metrics — Bio Path Holdings